Genetics/Genomics News

CAD has proved to be a highly preventable disease. Reduction in risk for CAD has been accomplished by changes in lifestyle such as cessation of smoking or lowering plasma cholesterol by drug therapy. Multiple randomized placebo-controlled clinical trials since the early 1990s targeting lowering of plasma cholesterol have consistently been associated with a 30% to 40% reduction in cardiac morbidity and mortality. Despite these efforts, CVD remains the most common cause of death in the U.S. and is also the most common cause of death throughout the world. Secondary prevention has been effective, whereas primary prevention offers even greater benefits and is more appropriate, if not necessary, to reduce this pandemic.

In patients with early-stage sarcomeric hypertrophic cardiomyopathy, valsartan improved certain parameters of disease progression compared with placebo, researchers reported at the European Society of Cardiology Congress.

The prevalence of clinical genetic testing is rising; therefore, the American Heart Association has issued guidance on the use, ethics and timing of pediatric genetic testing for heritable CVDs.

Studies showed that low enrollment of women in CVD clinical trials may be influenced by myriad clinical, racial and community-related factors, according to a perspective published in the Journal of the American College of Cardiology.

Cleveland Clinic has been selected by U.S. News & World Report as the top U.S. hospital for cardiology and heart surgery, in the publication’s 2021-2022 Best Hospitals rankings.

Beating cardiomyocytes were successfully grown from stem cells in space, which could have future implications for cardiac research.

Sharing results of genetic tests for cardiomyopathy with adolescents does not appear to negatively impact family functioning scores, researchers reported.

Healio and Cardiology Today have curated a list of the most read cardiology news of June 2021.

In a Mendelian randomization analysis, LDL reduction associated with statin use was linked to elevated odds of type 2 diabetes, but not with other pleiotropic effects.

In a phase 2 study, evinacumab reduced triglyceride levels in patients with severe hypertriglyceridemia but not familial chylomicronemia syndrome, a speaker reported at the American College of Cardiology Scientific Session.